Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2015 Feb;11(2):216-25.e1.
doi: 10.1016/j.jalz.2014.03.009. Epub 2014 Jul 9.

Follow-up evaluation of cognitive function in the randomized Alzheimer's Disease Anti-inflammatory Prevention Trial and its Follow-up Study

ADAPT-FS Research Group
Randomized Controlled Trial

Follow-up evaluation of cognitive function in the randomized Alzheimer's Disease Anti-inflammatory Prevention Trial and its Follow-up Study

ADAPT-FS Research Group. Alzheimers Dement. 2015 Feb.

Abstract

Objective: The Alzheimer's Disease Anti-Inflammatory Prevention Trial (ADAPT) and Follow-up Study (ADAPT-FS) examined effects of naproxen and celecoxib on cognition in the elderly. We report here results describing trajectories of cognitive evaluation test scores.

Methods: A total of 2356 participants completed baseline and at least one follow-up cognitive evaluation between 2001 and 2004. Study treatments were discontinued in 2004, but participants were followed until 2007. A total of 1537 participants were reevaluated in 2010 to 2011. Outcomes include seven cognitive evaluations administered yearly in person in ADAPT and three of these evaluations that were administered by telephone near the end of ADAPT and again in ADAPT-FS.

Results: There were no important differences over time by treatment group on any ADAPT cognitive measure, a global composite, or the three cognitive measures reassessed in ADAPT-FS by telephone.

Conclusions: Treatment for 1 to 3 years with naproxen or celecoxib did not protect against cognitive decline in older adults with a family history of AD.

Trial registration: ClinicalTrials.gov NCT00007189 NCT01417130.

Keywords: Alzheimer's disease; Celecoxib; Clinical trial; Cognitive function; Naproxen; Nonsteroidal anti-inflammatory drug; Prevention.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Raw scores for each of the 7 tests of cognitive function and the global summary over time
Figure 2
Figure 2
Global summary and 3MS-E by dementia diagnosis (during ADAPT or ADAPT-FS)
See this image and copyright information in PMC

References

    1. Szekely CA, Town T, Zandi PP. NSAIDs for the chemoprevention of Alzheimer's disease. Subcell Biochem. 2007;42:229–248. - PubMed
    1. Rozzini R, Ferrucci L, Losonczy K, Havlik RJ, Guralnik JM. Protective effect of chronic NSAID use on cognitive decline in older persons. J Am Geriatr Soc. 1996;44:1025–1029. - PubMed
    1. Jonker C, Comijs HC, Smit JH. Does aspirin or other NSAIDs reduce the risk of cognitive decline in elderly persons? Results from a population-based study. Neurobiol Aging. 2003;24:583–588. - PubMed
    1. Gray SL, Hanlon JT, Landerman LR, Artz M, Schmader KE, Fillenbaum GG. Is antioxidant use protective of cognitive function in the community-dwelling elderly? Am J Geriatr Pharmacother. 2003;1:3–10. - PubMed
    1. Hayden KM, Zandi PP, Khachaturian AS, et al. Does NSAID use modify cognitive trajectories in the elderly? The Cache County study. Neurology. 2007;69:275–282. - PubMed

Publication types

Associated data